Methods for Enhancement of Bioavailability: Exhaustive Study Guide

Characteristics of Drugs with Poor Bioavailability

Poor Aqueous Solubility and/or Slow Dissolution Rate: The drug has difficulty dissolving in biologic fluids, which is often the primary barrier to absorption.
Poor Stability at Physiologic pH: The drug may degrade or become inactive when exposed to the pH levels found in the gastrointestinal tract or other physiologic environments after dissolution.
Inadequate Partition Coefficient: The drug lacks the necessary balance between hydrophilicity and lipophilicity, resulting in poor permeation through biomembranes.
Extensive Pre-systemic Metabolism: The drug is heavily metabolized (e.g., by the liver or gut wall) before it reaches the systemic circulation, significantly reducing the amount of active drug available.

Major Approaches to Overcoming Bioavailability Problems

There are three primary strategic frameworks used to enhance the bioavailability of drugs:

The Pharmaceutic Approach: This involves modifying the formulation, the manufacturing process, or the physicochemical properties of the drug. Crucially, this approach does not involve changing the chemical structure of the drug itself.
The Pharmacokinetic Approach: In this method, the pharmacokinetics of the drug are altered by specifically modifying its chemical structure (e.g., forming a prodrug).
The Biologic Approach: This involves changing the route of drug administration (e.g., from oral to parenteral) to bypass biological barriers and metabolism.

The Pharmaceutic Approach: Detailed Methods

The pharmaceutic approach aims to enhance the dissolution rate, which is the major rate-limiting step in the absorption of most drugs. The following techniques are used:

1. Micronization

Process: Reducing the particle size of the drug to a range of $1$ to $10$ microns.
Techniques: Common methods include spray drying or fluid energy milling.
Mechanism: Reducing particle size increases the effective surface area available for interaction with fluids, which directly leads to higher dissolution rates.
Examples: This method is effective for drugs such as griseofulvin, various steroidal drugs, and sulfa drugs.

2. Use of Surfactants

Mechanism: Surface-active agents, such as polysorbates, promote the wetting of drug particles. This allows dissolution fluids to penetrate solid drug particles more effectively.
Example: The bioavailability of spironolactone is significantly improved through the use of surfactants.

3. Use of Salt Forms

Mechanism: Salts typically possess significantly improved solubility and dissolution characteristics when compared to the parent drug.
Examples:
- Alkali metal salts of acidic drugs: For example, penicillin salts.
- Strong acid salts of basic drugs: For example, atropine salts.

4. Alteration of pH of the Drug Microenvironment

Mechanism: Bioavailability is enhanced by adjusting the pH level immediately surrounding the drug particle to a value that favors its dissolution.
Methods of Achievement:
- In situ salt formation.
- The addition of buffering agents to the formulation.
Example: Buffered aspirin tablets.

5. Use of Metastable Polymorphs

Concept: Many drugs exhibit polymorphism, meaning they can exist in multiple crystalline forms.
Mechanism: Metastable forms are less stable but more soluble than the stable polymorphic form. Utilizing these metastable forms results in better bioavailability.
Example: The "B" form of chloramphenicol palmitate is used for its superior solubility over the stable form.

6. Solute-Solvent Complexation (Pseudopolymorphs)

Concept: These are also known as organic solvates.
Mechanism: Organic solvates generally have higher aqueous solubility than the original drug or its hydrate forms.
Technique Example: Freeze-drying a solute in an organic solvent can produce submicron particles.
Example: Griseofulvin-benzene solvate.
Requirement: Any solvent used in this process must be non-toxic.

7. Solvent Deposition

Process: A poorly aqueous soluble drug is first dissolved in an organic solvent. This solution is then deposited onto an inert, hydrophilic solid matrix, such as starch or microcrystalline cellulose, through evaporation.
Mechanism: This process improves the drug's contact with aqueous fluids.
Example: Nifedipine.

8. Selective Adsorption on Insoluble Carriers

Process: Highly active adsorbents, such as inorganic clays (e.g., bentonite), are used to adsorb poorly soluble drugs.
Mechanism: The drug is released rapidly because the physical bonding is weak. Furthermore, the clay's ability to swell in aqueous media maintains a high concentration gradient, facilitating dissolution.

9. Solid Solutions (Molecular Dispersions)

Structure: These are binary systems where a solid solute (the drug) is homogeneously and molecularly dispersed within a solid solvent (the carrier). This forms a one-phase system.
Mechanism of Action: When the system contacts water, the soluble carrier dissolves rapidly. This leaves the insoluble drug stranded at a molecular level, allowing for immediate solubilization.
Bioavailability Enhancement: Because the drug is reduced to a molecular level, solid solutions show greater solubility and faster dissolution than eutectic mixtures or standard solid dispersions.
Preparation Method: Usually prepared via the fusion method, where a physical mixture of drug and carrier is melted and then rapidly solidified. These are often referred to as "melts."
Specific Example: A griseofulvin-succinic acid melt (detailed in Fig. 1 as a binary phase diagram). Griseofulvin in this form dissolves $6$ to $7$ times faster than pure griseofulvin.
Glass Solutions: A subset of solid solutions that are transparent and brittle. Common carriers include citric acid, PVP, PEG, or various sugars.

10. Eutectic Mixtures

Definition: Physical mixtures of a drug and a soluble carrier that are completely miscible in a molten state but have negligible solid-solid solubility.
Preparation: Prepared by the fusion method (melting followed by rapid solidification).
Mechanism of Action: When gastrointestinal fluids contact the mixture, the soluble carrier dissolves fast, leaving the drug in a microcrystalline state. This state solubilizes much faster than larger drug particles.
Examples: Paracetamol-urea, griseofulvin-urea, and griseofulvin-succinic acid.
Advantages: Economical and easy to prepare without organic solvents.
Limitations: Unsuitable for thermolabile (heat-sensitive) drugs or carriers that decompose at their melting point. Products may be tacky or irregular in shape.
Phase Diagram: Fig. 3 displays a binary phase diagram where point E represents the eutectic point (the composition with the lowest melting point).

11. Solid Dispersions (Co-precipitates)

Preparation Method: Prepared via the solvent or co-precipitation method. The drug ("guest") and solid carrier ("host") are dissolved in a common volatile solvent (e.g., alcohol), which is then removed by evaporation or freeze-drying.
Physical State: The drug is precipitated in an amorphous form within a crystalline carrier, unlike the crystalline state in eutectic mixtures.
Bioavailability Enhancement: Increasing the dissolution rate by dispersing the drug at a submicron level in a soluble carrier.
Suitability: This is effective for thermolabile substances because it avoids high temperatures required for fusion methods.
Carriers: PVP, PEG, and urea.
Disadvantages: High processing costs, requirement for large volumes of organic solvents, and difficulty in ensuring full solvent removal.

12. Molecular Encapsulation with Cyclodextrins

Structural Features: Cyclodextrins (specifically beta- and gamma-cyclodextrin) have a unique dual nature: a hydrophobic (lipophilic) internal cavity and a hydrophilic outer surface (as seen in Fig. 5).
Mechanism: A "host-guest" relationship where a hydrophobic drug molecule (guest) is trapped inside the cyclodextrin’s cavity (host) to form molecular inclusion complexes.
Effect: This traps the drug in a hydrophilic lattice and reduces it to a submicron level, enhancing absorption efficiency in aqueous fluids.
Applications: Used for drugs with poor solubility like NSAIDs (e.g., salicylic acid), barbiturates, benzodiazepines, and thiazide diuretics.

The Pharmacokinetic Approach (Prodrugs)

This approach involves the chemical modification of the drug to change its inherent pharmacokinetic properties.

Prodrug Definition: The drug is converted into an inactive precursor designed for higher lipophilicity or stability.
Biotransformation: Once inside the body, the prodrug is converted (chemically or enzymatically) back into the active parent compound.
Purpose: To enhance membrane permeability (via increased lipophilicity), prevent pre-systemic metabolism, and improve chemical stability in the gastrointestinal tract.
Example: Pivampicillin is a prodrug of ampicillin that is more lipophilic and better absorbed.

The Biologic Approach

This approach focuses on changing the route of administration to bypass limitations in bioavailability.

Gastrointestinal Bypass: If a drug is unstable in the GI tract or suffers from extensive first-pass hepatic metabolism, parenteral routes (intravenous or intramuscular) are used.
Intravenous (IV) Administration: This results in $100\%$ bioavailability because the entire absorption process is bypassed.
Other Routes: Sublingual or buccal administration are used to bypass first-pass metabolism and prevent GI degradation.

Bioavailability is a critical measure of the rate and extent to which the active moiety is absorbed from a drug product and becomes available at the site of action. According to the transcript, a drug is characterized as having poor bioavailability if it possesses any of the following four traits: it has poor aqueous solubility and/or slow dissolution rate, making it difficult to dissolve in biologic fluids, which is often the primary barrier to absorption; poor stability at physiologic pH, where the drug may degrade or become inactive when exposed to the pH levels found in the gastrointestinal tract or other physiological environments after dissolution; an inadequate partition coefficient, where the drug lacks the necessary balance between hydrophilicity and lipophilicity, resulting in poor permeation through biomembranes; and extensive pre-systemic metabolism, where the drug is heavily metabolized before it reaches the systemic circulation, significantly reducing the amount of active drug available.

There are three primary strategic frameworks used to enhance the bioavailability of drugs. The pharmaceutic approach involves modifying the formulation, the manufacturing process, or the physicochemical properties of the drug without changing its chemical structure. The pharmacokinetic approach alters the drug's pharmacokinetics by specifically modifying its chemical structure, such as forming a prodrug. The biologic approach changes the route of drug administration, for example, from oral to parenteral, to bypass biological barriers and metabolism.

Focusing on the pharmaceutic approach, it aims to enhance the dissolution rate, which is a major rate-limiting step in absorption. Techniques employed include micronization, which reduces the particle size of the drug to a range of $1$ to $10$ microns, increasing the effective surface area for interaction with fluids. The use of surfactants promotes the wetting of drug particles, facilitating dissolution, as seen with spironolactone. Salts typically possess improved solubility and dissolution characteristics compared to the parent drug; examples include alkali metal salts of acidic drugs like penicillin and strong acid salts of basic drugs like atropine. Alteration of the microenvironment pH can enhance bioavailability by adjusting the pH surrounding the drug particle to favor dissolution.

Some other methods include employing metastable polymorphs, where less stable but more soluble forms of drugs are used; solute-solvent complexation, which enhances solubility and involves techniques like freeze-drying in an organic solvent; and solvent deposition, where a poorly soluble drug is dissolved in an organic solvent and deposited onto an inert carrier to improve contact with aqueous fluids. Selective adsorption on insoluble carriers using adsorbents like inorganic clays can also enhance the dissolution rate due to rapid release mechanisms. Solid solutions formed where a drug is molecularly dispersed within a solid carrier result in greater solubility, while eutectic mixtures and solid dispersions improve dissolution rates by facilitating fast release in gastrointestinal fluids.

Additionally, molecular encapsulation with cyclodextrins utilizes their unique structure to increase drug absorption efficiency by trapping the hydrophobic drug inside a hydrophilic lattice.

In the pharmacokinetic approach, prodrugs are chemically modified precursors designed for higher lipophilicity or stability. Designed for biotransformation in the body into the active drug, they aim to enhance membrane permeability and prevent pre-systemic metabolism.

Lastly, the biologic approach aims to change the route of administration to enhance bioavailability. For instance, intravenous administration achieves 100\text{%} bioavailability by bypassing the entire absorption process. Other routes such as sublingual or buccal administration are also essential to circumvent first-pass metabolism and degradation in the GI tract.